rs1057519991
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Combinations of the Y113H and H139R polymorphic EPHX1 variants have been assumed to alter the enzyme activity and thus the risk of squamous cell head and neck cancer (SCCHN).
|
12491039 |
2003 |
rs121912656
|
|
|
0.710 |
GeneticVariation |
BEFREE |
We show here that overexpression of the GOF mutant p53 G245D and other GOF p53 mutants enhances the invasive cell growth of p53-deficient head and neck squamous cell carcinoma (HNSCC) UM-SCC-1 cells both in in vitro three-dimensional culture and in an in vivo orthotopic nude mouse model of HNSCC through a novel transcription-independent mechanism.
|
29269868 |
2018 |
rs121912666
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Our analysis of p53 in 10 additional HLA-A2(+) SCCHN tumors detected the p53 Y220C in 2/10 tumors raising the overall frequency of the p53 Y220C mutation to 6/50 (12%) HLA-A2(+) SCCHN tumors.
|
17294448 |
2007 |
rs1042522
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Stratification analyses showed that a reduced risk associated with the -606CC genotype was more pronounced in subgroups of non-smokers, non-drinkers, younger subjects (defined as ≤57 years), carriers of the TP53 Arg/Arg (rs1042522) genotype, patients with oropharyngeal cancer or late-stage SCCHN.
|
20935061 |
2010 |
rs1042522
|
|
|
0.050 |
GeneticVariation |
BEFREE |
We found that RAD51 172TT homozygotes had a significantly decreased risk [adjusted odds ratio (OR) = 0.66, 95% confidence interval (CI) = 0.50-0.87] of SCCHN, compared with carriers of other genotypes, particularly in P53 Arg72Arg homozygotes (adjusted OR = 0.60, 95% CI = 0.41-0.89) (homogeneity test P = 0.047), although no alterations in the risk were associated with the RAD51 135G>C and P53 Arg72Pro SNPs.
|
17118968 |
2007 |
rs1042522
|
|
|
0.050 |
GeneticVariation |
BEFREE |
This study identified that individuals carrying the arginine allele at rs1042522 have an increased odds ratio of HNSCC.
|
26099726 |
2015 |
rs1042522
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Meta-analysis results indicated no association between p53 Arg72Pro polymorphism and the risk of HPV-related HNSCC: for Pro/Pro vs. Arg/Arg, OR = 1.17, 95% confidence interval (CI) = 0.70-1.98; for Arg/Pro vs. Arg/ Arg, OR = 1.25, 95% CI = 0.97-1.72; and for (Pro/Pro + Arg/Pro) vs. Arg/Arg, OR = 1.28, 95% CI = 0.95-1.70.
|
24289637 |
2013 |
rs1042522
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The meta-analysis showed no significant association between different allelic variants of Arg72Pro rs1042522 and SCCHN risk.
|
24370206 |
2014 |
rs1131691014
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We found that RAD51 172TT homozygotes had a significantly decreased risk [adjusted odds ratio (OR) = 0.66, 95% confidence interval (CI) = 0.50-0.87] of SCCHN, compared with carriers of other genotypes, particularly in P53 Arg72Arg homozygotes (adjusted OR = 0.60, 95% CI = 0.41-0.89) (homogeneity test P = 0.047), although no alterations in the risk were associated with the RAD51 135G>C and P53 Arg72Pro SNPs.
|
17118968 |
2007 |
rs1131691014
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The meta-analysis showed no significant association between different allelic variants of Arg72Pro rs1042522 and SCCHN risk.
|
24370206 |
2014 |
rs1131691014
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Meta-analysis results indicated no association between p53 Arg72Pro polymorphism and the risk of HPV-related HNSCC: for Pro/Pro vs. Arg/Arg, OR = 1.17, 95% confidence interval (CI) = 0.70-1.98; for Arg/Pro vs. Arg/ Arg, OR = 1.25, 95% CI = 0.97-1.72; and for (Pro/Pro + Arg/Pro) vs. Arg/Arg, OR = 1.28, 95% CI = 0.95-1.70.
|
24289637 |
2013 |
rs878854066
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The meta-analysis showed no significant association between different allelic variants of Arg72Pro rs1042522 and SCCHN risk.
|
24370206 |
2014 |
rs878854066
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Meta-analysis results indicated no association between p53 Arg72Pro polymorphism and the risk of HPV-related HNSCC: for Pro/Pro vs. Arg/Arg, OR = 1.17, 95% confidence interval (CI) = 0.70-1.98; for Arg/Pro vs. Arg/ Arg, OR = 1.25, 95% CI = 0.97-1.72; and for (Pro/Pro + Arg/Pro) vs. Arg/Arg, OR = 1.28, 95% CI = 0.95-1.70.
|
24289637 |
2013 |
rs878854066
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We found that RAD51 172TT homozygotes had a significantly decreased risk [adjusted odds ratio (OR) = 0.66, 95% confidence interval (CI) = 0.50-0.87] of SCCHN, compared with carriers of other genotypes, particularly in P53 Arg72Arg homozygotes (adjusted OR = 0.60, 95% CI = 0.41-0.89) (homogeneity test P = 0.047), although no alterations in the risk were associated with the RAD51 135G>C and P53 Arg72Pro SNPs.
|
17118968 |
2007 |
rs1057519975
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that RAD51 172TT homozygotes had a significantly decreased risk [adjusted odds ratio (OR) = 0.66, 95% confidence interval (CI) = 0.50-0.87] of SCCHN</span>, compared with carriers of other genotypes, particularly in P53 Arg72Arg homozygotes (adjusted OR = 0.60, 95% CI = 0.41-0.89) (homogeneity test P = 0.047), although no alterations in the risk were associated with the RAD51 135G>C and P53 Arg72Pro SNPs.
|
17118968 |
2007 |
rs1131691036
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that RAD51 172TT homozygotes had a significantly decreased risk [adjusted odds ratio (OR) = 0.66, 95% confidence interval (CI) = 0.50-0.87] of SCCHN</span>, compared with carriers of other genotypes, particularly in P53 Arg72Arg homozygotes (adjusted OR = 0.60, 95% CI = 0.41-0.89) (homogeneity test P = 0.047), although no alterations in the risk were associated with the RAD51 135G>C and P53 Arg72Pro SNPs.
|
17118968 |
2007 |
rs876659477
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Combinations of the Y113H and H139R polymorphic EPHX1 variants have been assumed to alter the enzyme activity and thus the risk of squamous cell head and neck cancer (SCCHN).
|
12491039 |
2003 |
rs1057519991
|
|
G |
0.710 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs121912656
|
|
T |
0.710 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs121912656
|
|
A |
0.710 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs121912656
|
|
G |
0.710 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs121912666
|
|
C |
0.710 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs121912666
|
|
G |
0.710 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs1057519747
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs1057519747
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |